Depot testosterone injections in men with metabolic syndrome and hypogonadism led to improvements in several important components of their disease, including significant weight loss and reduced glucose dysregulation, a researcher said here.
Interim results from a randomized, placebo-controlled trial showed that men receiving the hormone injections lost more than 4 kg (9 lb) in the first 30 weeks of a planned three-year study versus almost no change with placebo (P<0.001), reported Farid Saad, PhD, of Bayer Schering in Berlin.
Although fasting plasma glucose levels did not change, insulin levels dropped significantly among participants in the active treatment group, mainly among those with abnormally high levels at baseline, Saad told attendees here at the World Congress on Controversies to Consensus in Diabetes, Obesity, and Hypertension.
There were also trends toward normalized levels of certain blood lipids, serum leptin, and inflammation markers.
No comments:
Post a Comment